Drug Trial Radar · NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,132
Planned (sponsor's estimate)
Start
Mar 30, 2018
Primary completion
Sep 30, 2030
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences; Pfizer
- First posted
- Feb 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort). Cohort 3, 5, 6 and 7 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations. Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.
Conditions
- Metastatic Breast Cancer
Interventions
CapecitabineDrug
Capecitabine will be administered 1250 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day cycle.
AtezolizumabDrug
For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle. For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of each 28-day cycle.
IpatasertibDrug
Ipatasertib will be administered by mouth 400 mg once a day, on Days 1-21 of each 28-day cycle.
SGN-LIV1ADrug
SGN-LIV1A will be administered IV, 2.5 milligrams per kilogram (mg/kg) (maximum calculated dose 250 mg), on Day 1 of each 21-day cycle.
BevacizumabDrug
Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28-day cycle.
Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug
Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, on Days 1 and 8 of each 21-day cycle. Or Eribulin will be administered IV, 1.4 mg/m\^2 on Days 1 and 8 of each 21-day cycle.
SelicrelumabDrug
Selicrelumab will be administered by subcutaneous (SC) injection, at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (Cycle = 28 days).
TocilizumabDrug
Tocilizumab will be administered IV, 8 mg/kg on Day 1 of each 28-day cycle.
Nab-PaclitaxelDrug
Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
Sacituzumab GovitecanDrug
Sacituzumab govitecan will be administered by IV infusion, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
AbemaciclibDrug
Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle.
FulvestrantDrug
For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms: Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter. For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Palbociclib arms: Fulvestrant 500 mg, administered as an IM injection on Day 1 and as per local prescribing guidelines thereafter.
Ribociclib (Dose #1)Drug
Ribociclib tablets will be administered by mouth once daily.
Inavolisib (Dose #1)Drug
Inavolisib tablets will be administered by mouth once daily.
Trastuzumab DeruxtecanDrug
Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle.
Ribociclib (Dose #2)Drug
Ribociclib tablets will be administered by mouth once daily.
LetrozoleDrug
Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.
Inavolisib (Dose #2)Drug
Inavolisib tablets will be administered by mouth OD.
EmpagliflozinDrug
Empagliflozin, administered orally, once daily (QD)
PalbociclibDrug
For Empagliflozin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1 followed by 125 mg on Days 1-21 of each cycle. For Metformin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1, followed by 125 mg on Days 1-21 of each cycle (Cycle=28 days).
MetforminDrug
Metf 1000 mg administered orally QD.
AtirmociclibDrug
Atirmociclib administered orally, BID on Days 1-28 for each 28-day cycle.
GiredestrantDrug
Giredestrant 30 mg will be administered by mouth once daily, on Days 1-28 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Baseline until disease progression or loss of clinical benefit (up to approximately 12 years)
Locations
55 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope - Duarte
Duarte, California · Recruiting
City of Hope
Duarte, California · Completed
City of Hope - Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla
La Jolla, California · Recruiting
University of California San Diego Medical Center
La Jolla, California · Completed
UCLA Health 200 Medical Plaza
Los Angeles, California · Recruiting
Stanford Cancer Institute
Stanford, California · Withdrawn
Rocky Mountain Cancer Center - Longmont
Longmont, Colorado · Completed
H. Lee Moffitt Cancer Center and Research Inst.
Tampa, Florida · Completed
City of Hope® Cancer Center Chicago
Zion, Illinois · Recruiting
Metro-Minnesota Community Oncology Research Consortium
Saint Paul, Minnesota · Recruiting
Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
Omaha, Nebraska · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Hackensack Univ Medical Center
Hackensack, New Jersey · Withdrawn
Regional Cancer Care Associates, LLC
Howell Township, New Jersey · Withdrawn
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Withdrawn
NYU Langone Medical Center
New York, New York · Withdrawn
Duke Cancer Institute
Durham, North Carolina · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Withdrawn
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Withdrawn
Tennessee Oncology - Chattanooga Oncology & Hematology Associates
Chattanooga, Tennessee · Recruiting
The West Clinic
Germantown, Tennessee · Recruiting
Tennessee Oncology PLLC
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Texas Oncology-Plano East
Plano, Texas · Withdrawn
Peter MacCallum Cancer Centre-East Melbourne
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital - Medical Oncology
Murdoch, Western Australia, Australia · Recruiting
Centre Léon Bérard
Lyon, France · Completed
Institut régional du Cancer Montpellier
Montpellier, France · Withdrawn
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Recruiting
Universitätsklinikum Essen
Essen, Germany · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Shaare Zedek Medical Center
Jerusalem, Israel · Recruiting
Hadassah University Medical Center
Jerusalem, Israel · Recruiting
Rabin MC
Petah Tikva, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Israel · Recruiting
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.